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Abstract Neonatal hypoxic-ischemic (HI) injury still remains
an important issue as it is a major cause of neonatal death and
neurological dysfunctions. Currently, there are no well-
established treatments to reduce brain damage and its long-
term sequel in infants. Recently, reported data show that his-
tone deacetylase inhibitors provide neuroprotection in adult
stroke models. However, the proof of their relevance in vivo
after neonatal HI brain injury remains particularly limited. In
the present study, we show neuroprotective/neurogenic effect
of sodium butyrate (SB), one of histone deacetylase inhibitors
(HDACis), in the dentate gyrus of HI-injured immature rats.
Postnatal day 7 (P7) rats underwent left carotid artery ligation
followed by 7.6 % O2 exposure for 1 h. SB (300 mg/kg) was
administered in a 5-day regime with the first injection given
immediately after the onset of HI. The damage of the ipsilat-
eral hemisphere was evaluated by weight deficit. Newly pro-
duced cells were labeled with BrdU, at 50 mg/kg, injected
twice daily for 3 consecutive days. Subsequent differentiation
of the newborn cells was investigated 2 and 4 weeks after the
insult by immunohistochemistry using neuronal and glial cell-
lineage markers and BrdU incorporation. Finally, we per-
formed several behavioral tests to evaluate functional out-
come. In summary, SB led to a remarkable reduction of the
brain damage caused by HI. Moreover, the application of this
HDACi protected against HI-induced loss of neuroblasts and
oligodendrocyte precursor cells, as well as against neuroin-
flammation. The observed neuroprotective action suggests
that SBmay serve as a potential candidate for future treatment
of HI-evoked injury in neonates.
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Introduction
Neonatal hypoxic-ischemic encephalopathy (HIE) remains
one of the most important causes of neonatal mortality and
long-term neurological sequelae such as cerebral palsy, mental
retardation, epilepsy, and spastic paresis [1–4]. Encephalopathy
due to hypoxic-ischemic (HI) events derives from acute and
unpredictable episodes of perinatal asphyxia. The interruption
of blood supply to the brain leads to insufficient oxygen and
glucose delivery and triggers a cascade of biochemical events
including loss of energy, acidosis, excitotoxicity, elevation of
intracellular calcium, induction of oxidative stress, inflamma-
tion, and apoptosis, culminating in extensive brain damage [2,
5]. Undoubtedly, brain damage following hypoxia-ischemia is
a complex process and develops over several hours to days and
by this, it provides an opportunity for therapeutic intervention
in the sequence of intracellular processes induced by HI.
However, despite the significant progress in knowledge relating
themechanism(s) underlying evolving brain injury, there are no
well-established effective therapies to reduce brain damage and
its long-term sequel in infants. The clinical application of prom-
ising neuroprotective agents has been truly restricted due either
to inefficient or adverse effects.
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The lack of expecting effective neuroprotective treatments
for newborns suffering from HIE brings about increased inter-
est in alternative therapies based on stem cells, all the more
because neonatal HI brain injury stimulates a neurogenic re-
sponse. Although postnatal neurogenesis has been reported to
exist in many brain areas, it is seen most consistently in two
regions-subgranular zone (SGZ) of the hippocampal dentate
gyrus (DG) and the subventricular zone of the lateral ventri-
cles (SVZ). The HI-induced enhanced proliferation of neural
progenitors in these regions is followed by the migration of
newly generated cells toward the injured brain areas, where
they acquire the desired phenotype during the differentiation
process, enabling the damaged brain area to be reconstructed
[6–8]. However, it occurred that the endogenous repair pro-
cesses do not resolve the brain damage, as the capacity of
endogenous regeneration proved to be rather limited and in-
sufficient for replacing the lost neurons [9, 10]. Thus, strate-
gies are being sought to amplify the endogenous regenerative
response by introducing molecules that might expand stem
cell proliferation.
Recently, epigenetic agents have received considerable at-
tention and have spurned justified hope as therapeutic ap-
proaches against acute brain injury. Several data published
in the last decade provided significant evidence of neuropro-
tection obtained by histone deacetylase inhibitor (HDACi)
administration after stroke in the mature brain. The neuropro-
tective effect was associated with a decrease in brain lesion,
neurobehavioral improvement, and stimulation of
neurogenesis [11–17]. A significant amount of data suggests
that HDACis display protective properties also in a number of
neuropathological conditions. Therefore, it may be postulated
that treatment with these agents has emerged as an attractive
therapeutic approach in in vivo models of neurodegeneration
as well as in acute brain ischemia [16, 18–22].
Acetylation of histones is a key post-translational modula-
tion of proteins responsible for the regulation of critical intra-
cellular pathways. This process is carried out by two classes of
nuclear enzymes, histone acetylases (HATs) and histone
deacetylases (HDACs). Increased level of histone acetylation
is associated with the release of condensed chromatin and
enhanced gene transcription. Histone deacetylation, on the
other hand, promotes chromatin condensation and gene si-
lencing. Although histones are the most intensively investigat-
ed substrates, the activity of diverse non-histone proteins, such
as transcription factors, signal transduction mediators, is also
modified by HATs and HDACs [23, 24]. All these data imply
that the disruption of acetylation homeostasis may have a
serious impact on cellular functioning. This suggestion re-
mains in line with decreased level of acetylated histones in
neurodegenerative disorders as well as in brain ischemia insult
[18, 22].
HDACis have been shown to promote neuronal differenti-
ation of neural progenitor cells [25] via increased expression
of proneural genes Ngn1, Math1, and P15 [26] in association
with increased histone acetylation. Moreover, a number of
drugs with HDAC inhibitory activity have been shown to
protect mature neurons against acute brain injury [18, 27].
Despite mounting evidence concerning the role of HDACis
in neuroprotective/neurogenic processes in the experimental
ischemic model in adults, only a few studies addressed the
impact of HDAC inhibitors upon post-HI neurogenesis in
the immature brain [28–31]. Since many aspects of the evolv-
ing brain damage following hypoxic-ischemic insult, and
thereby the efficacy of neuroprotectants differs between adults
and neonates, extrapolating data obtained in the mature brain
to neonates is generally unwise. Therefore, the aim of our
study was to examine whether treatment with HDAC inhibi-
tor–sodium butyrate has neuroprotective/neurogenic effects in
a rat model of neonatal HI and, if so, to assess whether this
neuroprotection is associated with the decreasing HI-induced
functional deficits. Finally, based on previous reports indicat-
ing that growth factors released by brain ischemia-injured
cells may be crucial for the neurogenic response in adult ani-
mals, we sought to determine whether endogenous BDNF is
involved in the generation of new cells after hypoxic-ischemic
injury. Our attention was primarily focused on the hippocam-




All animal experiments were conducted according to a proto-
col approved by the Local Ethics Committee for Animal
Experimentation. Cerebral hypoxia-ischemia was produced
in 7-day-old (P7) Wistar rats of either sex by a permanent
unilateral common carotid artery ligation, followed by sys-
temic hypoxia [32, 33]. As was previously reported, the liga-
tion alone does not decrease cerebral perfusion below critical
levels, and the addition of hypoxia is required to cause brain
infarct [34]. Briefly, pups were anesthetized with isoflurane
(4 % induction, 2.0 % maintenance) carried by O2. Once they
were fully anesthetized, a midline neck incision was made and
the left common carotid artery was isolated, double ligated
with surgical silk, and cut between two ligatures. The incision
was then sutured with monofilament nylon. Sham-operated
animals underwent the same surgical procedure without the
ligation of the carotid artery. The time length of anesthesia
lasted on average 5 min. After surgery, the rat pups were
returned to their home cage for 1 h recovery. Hypoxia was
induced by placing the animals in a chamber (35 °C) and
subjecting them to a humidified mixture of 7.6 % oxygen in
nitrogen for 1 h.
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The undamaged hypoxic hemisphere, as well as age-
matched sham-operated animals, served as controls. Pups
from each litter were randomly assigned to 4 experimental
groups (5 rats per group and time point): (1) control group
(vehicle treatment) (2) control animals (SB treatment) (3) an-
imals which underwent HI (vehicle treatment), (4) animals
which underwent HI (SB treatment). Animals were sacrificed
at specific time points (3, 6, 7, 9, 11, 14 or 28 days) after the
injury.
Drug Administration and Bromodeoxyuridine Labeling
Rats subjected to HI or sham-operated were treated with sub-
cutaneous injections of sodium butyrate (SB, Sigma-Aldrich;
300 mg/kg body weight according to the published data [13,
14]) or vehicle (saline) starting immediately after hypoxic ex-
posure and lasting 5 consecutive days.
Endogenous cell proliferation was determined by 5-bromo-
2-deoxyuridine (BrdU) cell incorporation. BrdU (Sigma-
Aldrich) dissolved in physiological saline was administered
intraperitoneally (50 mg/kg per injection, in sterile 0.9 %
NaCl plus 0.007 N NaOH). Two-injection paradigms were
used. In the first paradigm, animals received a single dose of
BrdU and were sacrificed 24 h after the injection. This proce-
dure was used to determine the number of cells that incorpo-
rated BrdU during a 24-h period at a specific time point after
HI (3, 6, 9, 11, 14 days). In other experiments, the animals
received BrdU injections twice daily (12 h apart) for 3 con-
secutive days starting 4 days after the onset of hypoxia-ische-
mia. Animals in this group were sacrificed 14 and 28 days
after the insult. This allowed us to determine the phenotype
of newborn cells.
Brain Injury Evaluation
Fourteen days after the insult (at postnatal day 21), the pups
were anesthetized with 100 mg/kg ketamine combined with
10 mg/kg xylazine and decapitated, and the brains were dis-
sected. The brain stem and cerebellumwere removed from the
forebrain. The two cerebral hemispheres were separated in the
midline and weighed. The brain damage was assessed by the
weight deficit (%) of the ipsilateral (injured) hemisphere rela-
tive to the contralateral (hypoxic) hemisphere [35].
Tissue Preparation
At the scheduled time points, anesthetized animals were per-
fused transcardially first with phosphate buffered saline (PBS)
followed by a fixative solution (4 % paraformaldehyde, PFA,
in 0.1 M phosphate buffer, pH 7.4). The brains were removed
and submerged in the same fixative solution for 4 h at 4 °C.
Following postfixation, the brains were cryoprotected
overnight in 30 % sucrose solution (in 0.1 M PBS), frozen
rapidly using dry ice, and placed in −80 °C storage.
For biochemical analysis, animals were sacrificed through
decapitation and the hippocampi or whole hemispheres were
frozen on dry ice. All tissue samples were stored at −80 °C
until used.
Western Blot Analysis
Brain tissues were homogenized in RIPA lysis buffer (10 mM
Tris-HCl pH 7.5 containing 150 mMNaCl, 1 % Nonidet P40,
0.1 % SDS, 1 % Triton X-100, PMSF 0.1 mg/ml) and a pro-
teinase and phosphatase inhibitors cocktail (Life
Technologies, 1:100). Lysates were clarified by centrifugation
at 13,000 g for 10 min at 4 °C. The supernatant was collected
and used for analysis of BDNF (as described below). Cell
pellets were resuspended in RIPA lysis buffer. Protein concen-
trations were determined using a Bio-Rad DC™ protein assay
kit (Bio-Rad) in the supernatant as well as in the pellet solu-
tion. Samples of the pellet (50 μg protein) were ran on 10–
15 % SDS-PAGE gels and transferred onto nitrocellulose
membranes (Amersham Bioscience). After blocking, mem-
branes were probed with the polyclonal anti-acetyl H3 anti-
body (Millipore) and then incubated with horseradish
peroxidase-conjugated secondary IgG antibodies (Sigma-
Aldrich). Immunoblot signals were visualized using ECL
chemiluminescence kit (GEHealthcare Life Sciences). To ver-
ify an equal loading of protein per line, the beta-actin antibody
was used as an internal control for each immunoblotting.
Semi-quantitative evaluation of protein levels detected by im-
munoblotting was performed by computer-assisted densito-
metric scanning (LKB Utrascan XL, Program GelScan). The
level of protein immunoreactivity was determined by frequent
analysis of multiple immunoblots.
Immunohistochemistry
The following antibodies (source and final dilution) were used
for tissue staining: sheep polyclonal anti-BrdU (Abcam,
1:500), mouse monoclonal anti-BrdU (Santa Cruz
Biotechnology, 1:100), rabbit polyclonal anti-doublecortin
(DCX; Cell Signaling 1:200), rabbit monoclonal anti-
calbindin (Cell Signaling, 1:200), rabbit polyclonal anti-
NG2 chondroitin sulfate proteoglycan (Millipore, 1:200),
mouse monoclonal anti-oligodendrocyte marker (O4;
Millipore, 1:200), mouse monoclonal anti-myelin basic pro-
tein (MBP; Millipore, 1:200), and rat monoclonal anti-ED1
(CD68) (AbD Serotec, 1:100).
Coronal cryostat sections of the brain (30 μm thick) were
cut at the level of the dorsal hippocampus in serial order to
create 10 series sections. Double fluorescent immunohisto-
chemistry was performed on free-floating sections comprising
the hippocampal formation. After blocking for unspecific
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reactivity, adjacent series of sections were stained for a specif-
ic cell-lineage marker. For detection of BrdU incorporation,
DNAwas first denaturated by incubation of sections with 2N
HCl at 37 °C for 1 h and rinsed for 15 min in 0.1 M sodium
tetraborate (pH 8.5) at room temperature. After blocking with
10 % normal goat serum in PBS containing 0.25 % Triton X-
100 for 60 min and washing with PBS, sections were incubat-
ed with anti-BrdU overnight at 4 °C. Following the washing
procedure, the primary antibodies were revealed by appropri-
ate secondary FITC-conjugated (AlexaFluor, 1:500) antibod-
ies for 60 min at room temperature and in the dark.
Differentiation of BrdU-positive cells was monitored with
markers labeling neurons or oligodendrocytes at various
stages of maturation (DCX, calbindin, NG2, O4, MBP) and
microglia/macrophages (ED1). After BrdU staining, the brain-
tissue sections were incubated with primary antibodies over-
night at 4 °C. After being rinsed in PBS, the sections were
exposed to secondary antibodies for 1 h at room temperature.
Negative controls were processed in the same manner on ad-
jacent sections but with the primary antibodies omitted.
Double labeling to determine the expression of lineage
markers by BrdU expressing cells was verified using a confocal
laser scanning microscope (LSM 780, Carl Zeiss, Germany)
using a ×20 objective. A helium-neon laser (543 nm) was uti-
lized in the excitation of Alexa Fluor 546, while an argon laser
(488) was applied in the excitation of FITC.
The number of BrdU-positive cells in the entire DG area was
assessed in an average of five hippocampal sections per animal.
To avoid double counting, we did not analyze adjacent sections.
Every section was evaluated using a computerized system, and
the positive cells were displayed on a computer screen. All of
the counting was performed using ImageJ 1.46 software.
Quantitative Measurement of BDNF Protein
Concentration
To estimate the amount of BDNF in lysates obtained from the
hippocampi and hemispheres, the ChemiKine Brain Derived
Neurotrophic Factor, Sandwich ELISA (Millipore) test was
applied according to the supplier’s instructions. After
performing the Sandwich ELISA assay, the plates were read
at 450 nm using a spectrophotometric plate reader Fluorostar
Omega (BMG LabTech).
Behavioral Tests
Experimental animals were divided into three groups: control
(C), n = 12; hypoxia-ischemia (HI), n = 11; and hypoxia-
ischemia with sodium butyrate treatment (HI+SB), n = 12.
During behavioral experiments, rats were kept in a 12-h
light-dark cycle with water and food provided ad libitum.
The experiments were done during the light phase of the cycle.
Animal behavior was monitored at P33–83.
All testing and training were conducted by an observer
blind to the treatment group in a sound attenuated room.
Open field (OF) was initiated at P33–34 and performed for
3 days. OF box dimensions were 55 × 55 × 50 cm. Rats were
gently placed in the middle of the OF floor. The recording
lasted for 15 min. After each trial, the apparatus was cleaned
with 10 % ethanol solution. Animal behavior was recorded
with Basler acA1300-60 GigE camera (Bassler AG,
Germany) and scored using Ethovision XT 10 (Noldus
Information Technology, Netherlands). For the analysis, OF
floor was virtually divided into three zones: (i) border, 9.2 cm
wide; (ii) middle, 9.2 cm wide and (iii) center square,
18.3 × 18.3 cm. The following parameters were measured:
latency to the first entrance to a zone, frequency of entering
zones, percent time duration in each zone, mean velocity, and
total distance moved (comp. [36–38]).
Rotarod (accelerating Rota-Rod 7750,TSE systems,
Germany) was started at P39–40 and conducted according to
Karalis et al. [39]. On the first day only, the test was preceded
by habituation, i.e., placing the rat on a stationary cylinder for
30 s and thereafter for 2 min with a constant low-speed rota-
tion (4 rpm). Animals that fell from the rod were placed again
on it until they were able to stay for 60 s. After at least 10-min
rest, the animals were tested in accelerating conditions. The
cylinder accelerated from 4 to 40 rpm in 300 s. The time of the
trial was scored when the rat fell from the cylinder, spun with
the cylinder 3 times consecutively without walking or reached
a maximum of 500 s without falling. The device was cleaned
with 10 % ethanol solution between animals. Each rat was
scored once daily for 4 days.
Grip test (Bioseb BP, In Vivo research Instruments, France)
was initiated at P46–47 and done for 2 consecutive days [40,
41]. To measure the forepaw grip strength of the rat, it was held
by the trunk and the base of the tail. Then it was guided onto a
metal grid with 90.5 cm square opening, attached to a force
transducer, and encouraged to grab it by forepaws only. Then
the animal was steadily pulled backwards until it lost hold of the
grid. Threemeasurements in Newtons per rat were takenwith at
least 1 min of interval between trials to let the animal rest.
Morris water maze (MWM; comp. [42–44]) was started at
P62. The pool was 150 cm in diameter, the water temperature
was of around 25 °C, and it was dyed gray to discourage the
animals from diving. A square platform (10 × 10 cm) was
submerged 1.5 cm underneath the surface in the middle of
one of the quadrants. Rats’ home cages were left in the pool
room for at least 1.5 h to accommodate. For each trial, the rat
was placed on the platform for 60 s, and then it was put, facing
the walls of the pool, into the water at 1 of 4 starting positions.
The positions were pseudo-randomly varied from trial to trial,
with the restriction that in each series of 4 trials all 4 possible
positions had to be used. The animal had 60 s to find the plat-
form. In case of failure, the rat was guided to the platformwhere
it stayed for 60 s. There were 2 trials per day for 6 days. On the
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seventh day, the probe trial was performed with the platform
removed and the rats placed in the opposite quadrant. The trial
lasted for 60 s; it was repeated a week later. Animal behavior
was recorded and scored as in OF experiments. The visible
platform test was performed in the same conditions, but the
tank was covered around with curtains to remove visual cues
of the room. The platform was marked with a flag and placed
consecutively in 4 different positions. The rat was put into the
water in the opposite side of the pool related to the platform.
Time required for the animal to reach the platform was scored.
Ultrasonic vocalizations (USV) were evoked by tickling.
The procedure was initiated at P81 with some of the above-
mentioned animals (C, n = 6; HI, n = 6; HI+SB, n = 5). It
consisted of 2 days of pre-training with a familiar experiment-
er and the test day. The procedure was the same during pre-
training and the experiment. Namely, the rat was placed in the
tickling cage (57 × 38 × 20 cm) with a high sensitivity con-
denser microphone hung 30 cm above the center of the cage
floor. The rat waited for 30 s in the tickling cage before the
procedure. Then it was tickled for 15 s firstly by rapid finger
movement around the neck area and then by flipping the an-
imal on its back and rapidly moving fingers on its belly. The
next 15 s was spent by moving the experimenters hand around
the cage and allowing the rat to chase it. This was repeated 4
times [45]. USV were automatically scored on the spectro-
gram (Hamming, frame size 100 %, overlap 50 %) with
Avisoft SASLab Pro software.
Statistical Analysis
GraphPad PRISM 5.0 software was used for the statistical
analysis of the received data (excluding behavioral test
results). Comparisons between animal groups were per-
formed using one-way analysis of variance (ANOVA)
with post hoc Bonferroni test for multiple comparisons.
All values were expressed as mean ± SD. All data re-
ceived from behavioral tests are represented as means
with standard error of the means (SEM). The effects of
behavioral experiments were analyzed with ANOVAs.
Significant main effects or interactions were followed up
with post hoc analysis (Duncan), where appropriate. The
calculations were made using Statistica 7.1. (StatSoft Inc.,
2005).
Results
Effects of Sodium Butyrate on Brain Damage
All pups exposed to HI were lesioned in the left (ligated)
hemisphere. Dorsal view of the rat brain 2 weeks after the
insult presents damage (atrophy) of the ipsilateral hemisphere
and brain asymmetry. It should be noted that this model of HI
leads to different degree of damage reflecting individual re-
sponse to the insult (please compare Fig. 1a upper panel).
After SB treatment, none of the ligated hemispheres showed
atrophy. However, in a few cases, low degree of brain asym-
metry could still be visible (Fig. 1a lower panel left image).
In order to evaluate the effect of sodium butyrate on brain
damage caused by neonatal hypoxia-ischemia, we compared
the wet weight of ipsilateral hemispheres to the contralateral
ones. Two weeks after hypoxia ischemia, the mean weight
deficit of the ipsilateral (injured) hemisphere amounted
49.81 %, and it decreased to 27.05 % after SB treatment
(Fig. 1b). In the same conditions, the weight of the intact
contralateral side was not different from the respective sham
control.
The Effect of SB on the Acetylation of Histone 3
At first we measured the level of acetylated histone 3 (AcH3)
in rat brains after the application of 1, 3, or 5 doses of sodium
butyrate. A noticeable effect of SB was observed only after
3 days of treatment, which corresponds to postnatal day 10
(72 h of recovery after HI). Figure 2 shows respective repre-
sentative immunoblots probed with antibody specific to acet-
ylated histone H3 together with the densitometric analysis. As
depicted, the injection of SB resulted in significant increase of
AcH3 immunoreactivity by 54% over vehicle control, only in
sham-operated animals. In contrast, no statistically significant
changes in AcH3 level were noted in the investigated brains
after HI insult.
Time Course of Cell Proliferation in the Brain
Hippocampus
The time course of cell proliferation in the rat hippocam-
pus was studied at specific time points after hypoxic-
ischemic injury (3, 6, 9, 11, and 14 days after HI). For
this purpose, animals received a single dose of BrdU 24 h
prior to sacrifice. The number of newly generated cells
during 24 h was determined in the entire DG region of
the hippocampus by monitoring the incorporation and
subsequent immunohistochemical detection of BrdU.
BrdU-labeled cells were detected in all evaluated animals.
As evidenced by the analysis of hippocampal sections,
there was no difference in the number of proliferating
cells (BrdU+) between injured and control, sham-
operated animals. The highest density of BrdU incorpora-
tion was detected between 3 and 6 days of recovery.
Thereafter, cell proliferation decreased markedly in all
experimental groups, almost sevenfold, as compared with
the primary time point, indicating lowering of the dynam-
ic of stem/progenitor cell proliferation (Fig. 3a).
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Interestingly, the exposure to SB did not affect the number
of BrdU-positive cells in DG–neither in ipsi- nor in contralat-
eral side.
The distribution of BrdU-labeled cells throughout the brain
varies between the topographical areas. At 3 days of recovery,
a great number of dividing cells was seen in the hilus area.
With the prolongation of recovery to 9 and 11 days, BrdU+
cells are located almost exclusively in the neurogenic SGZ of
the DG (Fig. 3b).
Phenotypic Characterization of Proliferating Cells
after Neonatal Hypoxic/Ischemia
To further characterize the fate of newly arisen cells after SB
treatment, brain tissue sections from sham and HI rats were
double-stained for BrdU and different neural antigens–DCX
(for neuroblasts), calbindin (for mature granule neurons),
NG2 (detected in oligodendrocyte progenitor cells), O4 (for
immature, non-myelinating oligodendrocytes), and MBP (for
mature myelinating oligodendrocytes). For the purpose of
these studies, animals received multiple BrdU injections on
days 4–6 after hypoxia-ischemia and were sacrificed at 14 or
28 days of recovery. At first we investigated whether the treat-
ment with SB influenced cell proliferation in the hippocam-
pus. A striking proliferation of the precursor population was
seen at the investigated periods of recovery in the DG of
control and HI-injured rats, with the most pronounced expan-
sion of BrdU-positive cells at postnatal day 21 (which is
equivalent to 14 days after the insult). No significant differ-
ences were seen in the number of cells incorporating BrdU
when the hypoxic-ischemic DG was compared with the
Fig. 1 Sodium butyrate (SB) reduces brain damage after neonatal HI.
Neonatal HI was induced at postnatal day 7. SBwas administered directly
after the onset of HI and for 5 consecutive days. Brain damage was
evaluated 14 days after HI. The degree of damage was demonstrated as
the weight deficit of the ipsilateral (injured hemisphere) compared to the
contralateral one. a Dorsal view of rat brains at P21. Note the brain
asymmetry and atrophy in ipsilateral (left) hemisphere after HI (upper
panel). Treatment with SB after HI (HI+SB) prevents the atrophy;
however, a small degree of asymmetry is still visible (lower left image).
Abbreviations: C control, HI hypoxia ischemia. b Weight (g) of the
ipsilateral and contralateral hemispheres in rats with or without SB
treatment. The values are mean ± SD of 5 animals in each experimental
group. One-way ANOVA and Bonferroni test **p < 0.01 and
****p < 0.0001 indicate statistically significant differences.
Abbreviations: C control, ipsi ipsilateral, contra contralateral
Fig. 2 Sodium butyrate increases acetylation of histone H3 only in
control animals. a Representative immunoblot of AcH3 showing the
effect of SB in control animals and 72 h after HI, analyzed in four
experimental groups: vehicle control (C), SB-treated control (C+SB),
vehicle-treated hypoxia-ischemia (HI), SB-treated hypoxia-ischemia
(HI+SB). The intensity of each band was quantified by LKB Ultrascan
XL, Program Gel Scan, and normalized in relation to beta-actin. b
Statistical analysis of densitometric data from indicated experimental
groups. The values are mean ± SD from 5 animals that were assessed in
3 independent experiments. One-way ANOVA and Bonferroni test
**p < 0.01, control+SB vs. vehicle control. Abbreviations: C control,
ipsi ipsilateral, contra contralateral
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control. Also, the treatment with SB did not change the pattern
of proliferation response.
Double fluorescent studies revealed numerous BrdU-
positive nuclei in the neurogenic subgranular zone of DG
closely associated with neuronally committed precursors
and/or immature neurons (neuroblasts) expressing a
microtubule associated protein-DCX. DCX-positive cells
were extensively distributed in the DG of sham-operated con-
trol animals, as well as of the group treated with SB (Fig. 3a
upper panel and Fig. 3b). As shown by labeling and subse-
quent counts, the number of BrdU/DCX+ cells was signifi-
cantly decreased (by about 50%) in the hypoxic-ischemic side
at 14 days of recovery compared with controls (mean counts
24 vs. 50 BrdU/DCX-positive cells, respectively; p < 0.05). In
contrast, the number of cells in the side contralateral to liga-
tion, although also exposed to hypoxia, remained close to the
controls. It clearly appears that the administration of sodium
butyrate substantially increased BrdU/DCX-positive cells in
HI side to the value presented in sham (Fig. 4a left images in
the middle and lower panel and Fig. 4b). We also observed
that the number of neuroblasts slightly increased within the
DG of the hypoxic side; however, the changes were not sig-
nificant as compared to the vehicle-treated animals (Fig. 4b).
To check whether neuroblasts localized in the subgranular
zone of DG differentiate to mature neurons, we performed
double labeling assay using BrdU with calbindin—a marker
of granule neuronal cells. Quantified results are shown in
Fig. 5b. It clearly appears that 28 days after hypoxic-
ischemic injury, there is a significant decrease (more than
50 %) in double-stained BrdU/calbindin+mature granule neu-
rons in the DG region of the ipsilateral (hypoxic-ischemic)
side compared with controls (p < 0.001), without significant
effect noticed contralaterally. In contrast to the beneficial ef-
fect of SB on the number of neuroblasts in the ipsilateral DG,
in the same applied conditions, the inhibitor did not increase
the amount of newly generated granule neurons, which
remained persistently lower than control.
In order to evaluate the differentiation of newly produced
cells to oligodendroglial phenotype, we carried out double
fluorescent studies for BrdU and specific markers. To address
the question whether SB stimulates oligodendrogenesis within
the DG area, we analyzed the number of proliferating oligo-
dendrocyte precursor cells (OPCs) as well as more mature
oligodendrocytes in the sham and hypoxic-ischemic animals
after 2 and 4 weeks. For this purpose, we used antibodies
specific for cells being at a different developmental stage. In
control we observed a number of BrdU-labeled cells co-
stained with NG2, commonly used for the identification of
OPCs. As is shown in Fig. 6, 2 weeks after the hypoxic-
ischemic insult, we noted a marked decrease in new OPCs
(by about 75 % compared to sham control) ipsilaterally
(p < 0.0001); while the number of these cells in the contralat-
eral hypoxic side did not present statistical difference from the
control. Exposure to SB resulted in a significant raise in the
number of new progenitors in the ipsilateral (p < 0.001) as
well as in the contralateral (p < 0.01) side. The restoration of
the lost OPCs to the level of sham control and maintained
further at 4 weeks of recovery could be due, at least in part,
to the neuroprotective effect of this agent.
Fig. 3 Time course of cell proliferation in DG of the rat hippocampus
Animals received a single dose of BrdU (50 mg/kg) 24 h prior to
sacrifice at 3, 6, 9, 11, 14 days after HI and the brains were processed for
BrdU immunohistochemistry. a The number of BrdU-labeled nuclei within
the DG area in sham-operated control animals and at different times after
ischemia in both sides: injured ipsilateral and non-injured contralateral. The
highest number of proliferating cells was detected at 3–6 days after the
injury, thereafter the density of BrdU-positive cells markedly decreased.
The values are mean ± SD of 5 animals per group and time point. One-way
ANOVA and Bonferroni test did not indicate significant differences in
BrdU labeling between control (gray bars), ipsilateral (purple bars), and
contralateral hippocampi (green bars) in investigated time points. bNewly
divided cells in the HI-injured ipsilateral DG of the rat hippocampus.
Confocal photomicrographs show immunohistochemical reactions at 3,
6, 9, and 11 days after HI. While at 3 days of recovery the greatest number
of BrdU-positive cells is seen in the hilus, with the prolongation of recovery
time, their number becomes particularly pronounced in the neurogenic
SGZ of the hippocampus. Scale bar 200 μm
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Moreover, it was found that at the same time point
(4 weeks), the density of cells double-stained with BrdU/O4
(marker of the later-stage progenitor cells) in injured animals
did not differ from control group, as well as no differences
were noted in the density of cells that express MBP (marker of
mature oligodendrocytes). In addition, there was no visible
effect of SB either on the number of BrdU/O4 (Fig. 7) or
BrdU/MBP cells (data not shown).
Subsequently, based on several studies suggesting a strong
association of HI with inflammation, we examined the density
of microglial cells labeled for BrdU. As shown in Fig. 8, the
ipsilateral hemisphere exhibited a large number of microglial
cells assessed by double staining BrdU/ED1 at 14 days after
HI. SB treatment significantly suppressed cells expressing the
ED1 marker in the ligated hemisphere. It is important to point
out that these cells were not seen either in the contralateral side
or in age-matched sham-operated animals.
Contribution of Endogenous BDNF to SB Induced
Neurogenesis
According to the data indicating involvement of BDNF in
neurogenesis, maturation, and survival of newborn cells after
ischemic insult, we assessed whether the SB-induced genera-
tion of new cells correlates with the level of this neurotrophin.
BDNF was examined in hippocampi and in cerebral hemi-
spheres 3 and 7 days after hypoxia ischemia. We found that
in each experimental condition, the level of BDNF was sig-
nificantly higher at postnatal day 14 (corresponding to 7 days
of recovery) as compared to P10 (3 days of recovery) by about
36% in average. After hypoxic-ischemic injury, the amount of
BDNF remained close to the control value in both investigated
time points. The animal treatment with SB led to an increase
of BDNF level in the ipsilateral side at 7 days after HI
(p < 0.05; Fig. 9). The same direction of changes was
observed in the hippocampus; however, all described re-
sponses were more subtle and did not show significance.
Behavioral Testing
Open Field
On P33–34 the open field test was performed to assess the
animals’ response to a novel environment, their activity, and
locomotion abilities. There was an effect of the day
F(2,62) = 7.3, p < 0.01, reflecting shortening of the distance
traveled in consecutive days, but no effect of the group
F(2,31) = 0.5, p = 0.61, and no group × day effect
F(4,62) = 1.0, p = 0.42. Day differences were confirmed by
post hoc analysis in HI group (day 1 vs. day 3, p < 0.05) and in
HI+SB group (day 1 vs. day 3, p < 0.05) (Fig. 10a). The results
of velocity paralleled these results. There were no other dif-
ferences for duration and frequency in OF zones. Results of
this experiment reflect that the administration of SB does not
influence the response of animals to novelty or their locomo-
tor skills.
Rotarod
On P39–40 the rotarod test was carried out to assess coordi-
nation, balance and gross motor functions. There was only an
effect of the day, F(3,60) = 3.4, p < 0.05, reflecting general
tendency for the animals to stay on the rod longer from day to
day, with no group effect F(2,20) = 2.1, p = 0.15. However, a
direct comparison (one-way ANOVA) of the first day results
between sham control (165.1 ± 15.2 N) and HI animals
(124.1 ± 12.1 N) (F(1,14) = 4.1, p = 0.06) and between control
and HI+SB rats (101.4 ± 14.0 N) (F(1,19) = 9.3, p < 0.01)
suggest that the latency to fall was reduced in HI rats com-
pared to age-matched controls (Fig. 10b).
Grip Test
To quantify the impact of HI and SB administration on the
muscular strength of animals, we used the grip test starting
from day P46–47. There was no group (F(2,32) = 1.5,
p = 0.24), and no day (F(1,32) = 0.1, p = 0.74) effect, illus-
trating that neither HI nor SB affected the grip strength of
forelimbs.
Morris Water Maze
Spatial learning and memory were assessed in animals starting
from P62 using the Morris water maze test. We noticed longer
latencies to reach the platform in hypoxia-ischemia rats when
compared to control animals, while SB treatment had no ma-
jor influence. After several days of learning, all animals
showed shorter latencies in reaching the platform, with a
Fig. 4 Sodium butyrate promotes generation of new neuroblasts in the
DG after HI. Neonatal HI was induced at postnatal day 7. SB was
administered directly after the onset of HI and for 5 consecutive days.
BrdU was administered twice daily for 3 consecutive days starting 4 days
after the onset of HI. Brain sections from control animals and from
animals 14 days after HI were double-labeled with anti-BrdU (green)
and anti-DCX (red) antibodies. a Confocal photomicrographs show
double-labeled cells in DG of control (C) and HI animals 14 days after
the insult, with or without SB treatment. Inserts represent magnification.
Note that HI led to a marked decrease of BrdU/DCX-positive cells in the
injured, ipsilateral side, and the density of new neuroblasts clearly
increased after SB treatment. b Number of BrdU/DCX-positive cells
quantified in the DG area (0.36 mm2) in sham-operated control animals
and 14 days after HI in the injured ipsilateral as well as in the non-injured
contralateral side. The values are mean ± SD of 5 animals per
experimental group. One-way ANOVA and Bonferroni test indicate
significant differences in double labeling between investigated groups,
*p < 0.05 ipsilateral HI vs. control and ****p < 0.0001 ipsilateral HI




strong effect of the day F(5160) = 9.3, p < 0.001. There was
also a general effect of the group F(2,32) = 3.8, p < 0.05 as
well as a group × day effect F(10,160) = 3.7, p < 0.001. Post
hoc analysis showed a decrease in latency to reach the plat-
form (Fig. 10c) in control rats (p < 0.001) as well as in HI+SB
group (p < 0.01) and almost significant effect in HI rats
(p = 0.08). Also, toward the end of the training (days 4–6),
there was a difference between control and HI rats on day 4
(p < 0.01), day 5 (p < 0.05), and day 6 (p < 0.05), whereas
there was no significant difference between control and HI+
SB rats during these days (p > 0.05, Duncan). However, the
results of HI+SB animals closely paralleled these of HI rats
toward the end of the training. Thus, results obtained from this
test suggest that HI animals have a more impaired memory
performance than those with SB administration when com-
pared to control animals.
Ultrasonic Vocalizations (USV)
The evaluation of social and emotional behaviors was done by
measuring the rates of 50 kHz USV. HI and HI+SB animals
displayed less USV then control animals, especially when
following the experimenter’s hand. There was no significant
effect of SB administration observed, i.e., no difference
Fig. 5 Sodium butyrate does not
increase the number of newly
generated granule neurons in the
DG after HI. Neonatal HI was
induced at postnatal day 7. SB
was administered directly after
the onset of HI and for 5
consecutive days. BrdU was
administered twice daily for 3
consecutive days starting 4 days
after the onset of HI. Brain
sections from control animals and
from animals 28 days after HI
were double-labeled with anti-
BrdU (red) antibody and the
granule cell marker-calbindin
(green). a Confocal photomicro-
graphs show double-labeled cells
in the ipsilateral (injured) and
contralateral side of DG 28 days
after HI with or without SB treat-
ment. Inserts represent magnifi-
cation. Photomicrographs are
representative of observations
made from 5 animals per experi-
mental group. Scale bar 50 μm. b
Number of BrdU/calbindin-
labeled cells quantified in the DG
area (0.36mm2). Values represent
mean ± SD of 5 animals per time
point. One-way ANOVA and
Bonferroni test indicate signifi-
cant differences in double-labeled
cells between investigated
groups, *p < 0.05 ipsilateral HI
vs. contralateral HI, ***p < 0.001,
ipsilateral HI vs. control,
****p < 0.0001, ipsilateral HI+




between HI and HI+SB groups. However, as can be observed
in Fig. 10d, the number of USV emitted by control animals
was higher than in case of HI and HI+SB rats. This effect was
especially visible during follow sessions. When average num-
bers of USV from all follow sessions were analyzed
(ANOVA), there was the effect of group F(2,14) = 3.8,
p < 0.05; with differences between control (40.0 ± 3.5 USV)
vs. HI (23.9 ± 6.4) animals (p < 0.05) as well as control vs.
HI+SB rats (21.1 ± 5.6) (p < 0.05, Duncan). While there was
no group effect for average USVemitted during play sessions,
F(2,14) = 0.7; p = 0.51; control rats, 36.8 ± 3.0; HI rats,
30.8 ± 7.4; HI+SB rats, 28.3 ± 3.4 USV). Results obtained
in this task suggest that HI affected USVemissions at anatom-
ical and/or behavioral levels.
Discussion
The present study showed that treatment with histone
deacetylase inhibitor-sodium butyrate after HI provides neu-
roprotection. The neuroprotective effect of HDACi was con-
nected with a reduction of brain damage when measured at
14 days after the onset of hypoxia-ischemia, as well as in-
creased neurogenesis. The striking features of our results were
that neuroprotective/neurogenic effects of SB observed in our
study were associated with expanded population of
neuroblasts detected by staining with BrdU/DCX, expansion
of oligodendrocyte precursor cells (BrdU/NG2-positive) as
well as inhibition of HI-induced inflammation. However, in
contrast to our expectation, we did not observe significant
improvement of the behavioral impairments seen in MWM
and USV, which resulted from HI.
Neonatal hypoxia-ischemia sets in motion a series of path-
ophysiological processes that result ultimately in the massive
loss of neurons and severe neurological deficits, despite the
enhanced neurogenic response subsequent to neonatal brain
injury. It is of note that many experimental studies have shown
an increased number of proliferating neural progenitor cells
residing in the active SVZ. Furthermore, these give rise to
neuroblasts that migrate into the ischemia-damaged structure.
However, in spite of these interesting and important findings,
there remains much doubt regarding the regenerative capacity
because the expected long-lasting effect on neuron numbers
was not noticed [6, 46, 47]. A few papers evaluating the pro-
liferative capacity in the second neurogenic area-hippocampal
SGZ, reported inconsistent data: either increased [46] or re-
duced [7, 48] total counts of new cells. These obvious discrep-
ancies could be explained by differences in experimental con-
ditions including, among others, BrdU injection protocols,
which undoubtedly contribute to the variability in the number
of BrdU-positive cells among the animals. During the course
of our study, we selected a BrdU administration protocol (4–
6 days after lesioning) on the basis of our experimental results
as well as on the results of adult rodent stroke studies [49]. We
anticipated that this paradigm would be optimal for labeling
newly generated cells. Quantitative analysis of BrdU labeling
in tissue samples gained 2 and 4 weeks after the injury shows
that the population of proliferating cells in the ipsilateral as
well as in contralateral DG is close to age-matched sham-
operated animals. This observation is consistent with data re-
ported previously by Qiu et al. [50] in mice subjected to HI.
Thus, it may be supposed that the immature hippocampus is
already working at the top of its proliferative capacity in this
stage of development. It is also probable that the pool of pro-
genitors might be preferentially protected against ischemic
depletion. The unchanged intensity of proliferation found in
this study remains in striking contrast with a marked suppres-
sion of the population of new neuroblasts (BrdU/DCX) as
well as newly matured granule neurons (BrdU/calbindin-pos-
itive) in the HI-injured ipsilateral side of the hippocampus.
Then, it may be concluded that contrary to what has been
assumed previously, the endogenous spontaneous
neurogenesis is insufficient for replacing the lost neurons
and to achieve global repair of neonatal brain injured by HI.
The present study demonstrates that despite the severity of
brain pathology induced by neonatal HI, administration of
sodium butyrate for 5 days following the onset of the insult
appeared to decrease the cerebral damage by preventing se-
vere atrophy or brain asymmetry. Our findings are in general
agreement with those reported previously that histone
deacetylase inhibitors (VPA, TSA and SB) exhibit a neuropro-
tective effect in cerebral injury induced in adult rodents [13,
14, 16]. Thus, based on the beneficial effects proven in the
above studies, the potential use of HDACis for the mobiliza-
tion of endogenous progenitors seemed to be reasonable as a
therapeutic avenue for restoring the damaged neonatal brain.
Yet, only a few papers have presented neuroprotective action
of these agents in the immature brain and those addressing the
impact of HDAC inhibitors upon post-injury neurogenesis
remain particularly limited [28–31]. Moreover, the aims of
the mentioned above studies do not always include the assess-
ment of maturation of the proliferating cells into neurons and
other cell types.
We assumed that the reduced deficit of weight in the
hypoxic-ischemic hemisphere after SB administration reflects
compensatory formation of new cells. Surprisingly, it occurred
that SB did not enhance the population of dividing cells in
DG. Aswas mention above, it may be due to a maximal rate of
cell proliferation in the chosen stage of brain development and
then, it cannot be upregulated any further by epigenetic ma-
nipulation. Otherwise, exposure to SB restored the lost
neuroblasts in the ipsilateral SGZ 14 days after HI. This find-
ing raises the possibility that new cells will participate in the
recovery by supplementing new neurons. This prediction was
reinforced by the fact that neuroblasts express DCX, a marker
with multiple beneficial functions including migration,
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differentiation, and survival. However, in contrast to our ex-
pectation, the number of newly generated cells positive for
both signals, BrdU and calbindin, present throughout the gran-
ular cell layer, did not return to the control level, despite the
apparently robust production of immature neurons after expo-
sure to SB.
At present a clear picture of the critical initial signaling
events responsible for the insufficient neurogenesis in the
presence of SB remains elusive. One of the most likely expla-
nations is that the injured SGZ does not provide an environ-
ment that is conducive to the maturation or survival of the
newly formed neurons, which is in agreement with other pub-
lished data [8, 51, 52]. It is supposed that an anti-neurogenic
environment counteracts maturation of neuroblasts and may
contribute to the predominant glial fate in vivo, much like in
the adult brain [53]. Thus, it follows, that in our experimental
conditions, the expected SB-induced regenerative capacity
fails as a source of meaningful compensation for lost neuronal
circuits. According to the results of the detailed elegant study
performed by George et al. [29], the impact of HDAC inhib-
itors upon post-stroke neurogenesis is likely to depend on
many factors, including the age of the animal at the timewhere
neurogenesis is assayed, duration of HDAC inhibition before
the BrdU labeling, and/or stage of the evolution of injury. Our
results remain in disagreement with reports indicating that SB,
as well as other inhibitor treatments, induced neuronal cell
differentiation in brain areas injured by ischemia and may
contribute to long-term beneficial effects in adult rodents
[13, 16].
Neonatal hypoxic-ischemia led to marked reduction in the
number of oligodendrocyte progenitor cells (OPCs;
BrdU/NG2), pronounced in the ipsilateral hippocampus.
This response remains in agreement with already published
data showing susceptibility of oligodendrocytes to neonatal
HI injury [6, 54, 55]. OPC depletion may lead to impairment
of oligodendrocyte maturation at a premyelinating develop-
mental stage and in consequence to white matter damage [56].
However, the markers attributed to more advanced stages of
oligodendrocyte maturation (BrdU/O4-positive cells) seem to
be similarly distributed in control and injured animals at
4 weeks after HI. It might be due to ongoing compensation
by the active gliogenesis process which is known to proceed
most intensely during both the perinatal period and the first
postnatal weeks in rats [57–59]. Since OPCs are supposed to
be generated in excess during ontogenesis, the number of
mature oligodendrocytes is often reported to be normal in
spite of their decreased number after insults [60, 61]. This
implies the protection of myelin formation which is still in
active state in neonates [62].
Post-insult treatment with SB-histone deacetylase inhibitor
robustly increased the number of OPCs in both hippocampi at
2 and 4 weeks of recovery reinstating the physiological pool
of OPCs, which could contribute to sustain endogenous ho-
meostasis. The present data are consistent with findings from
in vitro studies pointing to the role of SAHA, another HDACi,
in preserving mature oligodendrocytes in the mouse optic
nerve after OGD [63]. On the other hand, Fleiss et al. [28]
using a model of lipopolysaccharide-sensitized hypoxia-is-
chemia found that trichostatin A, which is also a common
inhibitor of HDAC, did not affect the insult-reduced oligoden-
drocyte number, what could be observed by Olig-2 staining.
The obvious differences could be due to different investiga-
tion models. It is worth to point out that there are also inter-
esting but intriguing data indicating that just HDAC activity is
essential for oligodendrocyte differentiation in the developing
rodent brain [64–68]. Of note, activity of class I histone
deacetylases (HDAC1 and HDAC2) is required to regulate
oligodendrocyte differentiation and maturation by reducing
the expression of co-repressors of myelin gene transcription
[68, 69]. Furthermore, genetic ablation of both isoforms in the
mouse blocks these processes [68]. However, it seems rather
hard to compare the study conducted by Ye et al. [68] in non-
pathological experimental conditions with hypoxic-ischemic
brain injury performed in our study. Therefore, considering
our data we cannot negate the role of HDAC inhibition in
mediating the effect observed in the course of our
investigation.
One of the interesting findings obtained in the current work
is that the protective effect of SB on oligodendrocyte progen-
itors seen in the ipsilateral hemisphere 2 weeks after the insult
was associated with reduction of HI-induced microglial cells
and infiltration of macrophage/monocytes (ED1-positive). It
might be one of the potential mechanisms whereby SB pro-
tects oligodendrocytes. This is generally consistent with re-
ported earlier correlation between oligodendrocyte protection
and suppression of the proinflammatory action of microglia/
macrophages in adult rodents [15, 70, 71]. Convincing
Fig. 6 Sodium butyrate stimulates oligodendrocyte precursor cell
proliferation in DG of the rat hippocampus after HI. Neonatal HI was
induced at postnatal day 7. SB was administered directly after the onset of
HI and for 5 consecutive days. BrdU was administered twice daily for 3
consecutive days starting 4 days after the onset of HI. Brain sections from
control animals and from animals 14 days after HI were double-labeled
with anti-BrdU (green) antibody and the oligodendrocyte precursor cell
marker–NG2 (red). a Confocal photomicrographs of control and HI
ipsilateral and contralateral side of DG with or without SB treatment.
Note the decreased number of double-labeled cells (BrdU/NG2-positive)
in the ipsilateral side as compared to the control. The density of new
oligodendrocyte progenitors increases after SB treatment in both
hemispheres-ipsi- and contralateral. Inserts represent magnification.
Photomicrographs are representative of observations made from 5
animals per experimental group. Scale bar 50 μm. b Graph shows the
number of BrdU/NG2-labeled cells quantified in the DG area (0.36mm2).
Values represent mean ± SD of 5 animals per experimental group. One-
way ANOVA and Bonferroni test indicate significant differences in
double-labeled cells between investigated groups, ***p < 0.001,
contralateral HI vs. contralateral HI+SB, ****p < 0.0001, ipsilateral HI
vs. control, and ipsilateral HI vs. ipsilateral HI+SB. Abbreviations: C
control, IPSI ipsilateral, CONTRA contralateral
R
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evidence showed that in some conditions HDACis induced
microglial apoptosis to protect against neuronal death [72].
The effects of HDAC inhibition described above may also,
in addition, improve the environmental milieu surrounding
nearby neurons and indirectly exert a neuroprotective effect.
At present we cannot outline precisely the molecular
mechanism(s) directly linked to the observed beneficial
effects of sodium butyrate after neonatal HI. One, most
probable scenario, is the increased acetylation of histones
which is a virtue of HDAC inhibitory activity. Indeed,
HDACi treatment has been reported to be associated with
marked upregulation of AcH3 in the DG after ischemia in
adult rodents [14, 16]. In our study SB application elicited
an increase in acetylated histone H3 level only in sham
(control) animals. In contrast to others, the same mode of
SB application after hypoxia-ischemia did not result in the
elevation of histone acetylation above the vehicle control
value. The unchanged acetylation after HDACi injection
was also described by [28] in male mice in a model of
LPS/HI. The unexpected lack of HDACi effect could be
due to stress response of post-injured tissue which tempo-
rarily induced inhibition of histone acetyltransferase activ-
ity and/or overactivation of HDAC during this stage of
development. This prediction may be reinforced by data
reported by Sandner et al. [31] showing prolonged (last-
ing 4 months) overactivation of HDAC after hippocampal
Fig. 7 SB does not influence the
number of oligodendrocytes
expressing O4 in DG of the rat
hippocampus after HI. Neonatal
HI was induced at postnatal day 7.
SB was administered directly
after the onset of HI and for 5
consecutive days. BrdU was
administered twice daily for 3
consecutive days starting 4 days
after the onset of HI. Brain
sections from control animals and
from animals 28 days after HI
were double-labeled with anti-
BrdU antibody (green) and the
non-myelinating oligodendrocyte
marker–O4 (red). a Confocal
photomicrographs show double-
labeled cells in the ipsilateral
(injured) and contralateral side of
DG 28 days after HI with or
without SB treatment. Inserts
represent magnification. Note the
similar density of BrdU/O4-
positive cells in indicated
sections. Photomicrographs are
representative of observations
made from 5 animals per
experimental group. Scale bar
50 μm. b Number of BrdU/O4-
labeled cells quantified in the DG
area (0.36 mm2). Values represent
mean ± SD of 5 animals per time
point. One-way ANOVA and
Bonferroni test did not indicate
significant differences in the
number of double-labeled cells
between the investigated groups.
Abbreviations: C control, IPSI
ipsilateral, CONTRA contralateral
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lesioning. If such an event took place during the time of
our assay, it may account, at least partially, for the lack of
SB influence. On the other hand, it is also possible that
the evolving inflammatory response to HI injury may tem-
porarily suppress HDAC activity producing a lack of re-
sponse to inhibitors [73]. Nevertheless, our results, inde-
pendent of the above considered mechanism, may reflect
a novel equilibrium reached between acetylation and
deacetylation processes in order to maintain the proper
gene transcription. We can state that the effects of sodium
butyrate treatment do not seem to be achieved through
increased acetylation of histone H3. Histones are not the
sole substrate of HDACs. Several of histone deacetylase
isoforms have been shown to regulate acetylation of a
plethora of non-histone proteins, and thus, we cannot rule
out the possibility that the neuroprotective effect of
HDAC inhibitors are multifold and linked to influencing
a diverse array of targets [24, 27].
Fig. 9 Sodium butyrate increases the level of BDNF in the ipsilateral
hemisphere after HI. Graph represents the BDNF level in cerebral
hemispheres (ipsi- and contralateral) in four investigated groups:
vehicle-treated control (C), SB-treated control (C+SB), vehicle treated
hypoxia-ischemia (HI), and SB-treated hypoxia-ischemia (HI+SB). The
values are mean ± SD from 5 animals per group that were assessed in two
independent experiments. The level of BDNF was significantly higher
7 days after HI as compared to 3 days of recovery. One-way ANOVA and
Bonferroni test, *p < 0.05, indicate statistically significant differences
between ipsilateral hemispheres from rats receiving SB (HI+SB) vs.
vehicle (HI)
Fig. 8 Sodium butyrate reduces microglial cell number in the rat
ipsilateral hemisphere after HI. Neonatal HI was induced at postnatal
day 7. SB was administered directly after the onset of HI and for 5
consecutive days. BrdU was administered twice daily for 3 consecutive
days starting 4 days after the onset of HI. Brain sections from an SB-
treated as well as untreated ipsilateral rat hemispheres were double-
labeled with anti-BrdU (green) and ED1 (marker for microglia and
macrophages) antibody 14 days after HI. Confocal photomicrographs of
ipsilateral hemispheres show a large number of double-stained cells
(BrdU/ED1-positive) after HI and marked reduction after SB treatment.
Photomicrographs are representative of observations made from 5 ani-
mals per experimental group. Scale bar 50 μm. Abbreviations: IPSI
ipsilateral
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One of the HDACi targets known to be involved in
neurogenesis and survival of newborn cells after ischemic
insult is BDNF [74, 75]. HDAC inhibition activates
BDNF promoter IV and increases BDNF mRNA levels
in dissociated rat cortical neurons [76]. The increased
BDNF level in the ipsilateral hemisphere found in our
study after SB treatment may imply that trophic support
plays a role in neurogenesis. This hypothesis has been
intensified by reports showing that administration of en-
dogenous BDNF after HI in neonates decreased brain
damage [77]. Furthermore, the role of BDNF-TrkB signal-
ing in mediating HDACi-induced cell proliferation and
differentiation in the ischemic adult rodents was support-
ed by several findings [13, 71]. Thus, at least, this mech-
anism mediated by BDNF underpinning neuroprotection
after SB treatment in neonates is supposed to be one of
those commonly reported in adult cerebral studies. To
define the role of BDNF, further studies are needed.
One would expect that the neuroprotective/neurogenic
effects of SB found in our study after HI induced in neo-
natal rats would be further translated to improving the
neurobehavioral performance. To this end, we employed
sensorimotor as well as cognitive tests to assess motor
coordination and memory deficits in animals after HI,
treated and untreated with SB. It was expected that by
the t ime of test ing (P33–P83), newly generated
neuroblasts became fully matured. In contrast, their num-
ber still remained below control level in the ipsilateral
side after HI as well as after SB treatment. Only in two
of the five individual tests performed (MWM and USV
recording), HI-injured rats showed significant behavioral
deficiency when compared to controls. Mildly impaired
cognitive function observed in other tests performed indi-
cate that HI-treated rats showed some degree of recovery
as it has also been suggested by previous studies [78, 79].
Administration of the histone deacetylase inhibitor after
the onset of the insult did not counteract significantly
the functional brain impairments caused by HI; however,
there was a tendency for improving learning, as is seen in
graph presenting the results of MWM. In spite that SB
protected against ischemia-induced damage of brain struc-
tures contributing to several cognitive processes [80, 81],
the remaining number of new-generated mature neurons
probably occurred to have insufficient potential for the
Fig. 10 SB treatment does not affect behavioral outcome after HI.
Animal behavior was monitored at P33–79 in three investigated groups:
control (C), hypoxia-ischemia (HI), and hypoxia-ischemia treated with
SB (HI+SB). Schemes represent the data of indicated tests. Open field (a)
and RotaRod (b) test results show a lack of difference between
investigated groups (control, HI, HI-treated with SB). Morris water
maze (MWM) (c) and ultrasonic vocalizations (USV) recording (d)
results illustrate behavioral deficiency in rats after HI with some tendency
for improvement after SB treatment in MWM. The results are presented
as mean ± SEM. One-way ANOVA and Duncan test *p < 0.05,
**p < 0.01
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compensation of interplay between hippocampus and pre-
frontal cortex. Thus, the rescue of neurobehavioral defi-
cits needs restoration of the granule cell layer and preser-
vation of the neural networks. Our data are similar to
those reported by Sandner et al. [31] showing that
HDAC inhibitor injected for as long as 7 weeks was suf-
ficient to alleviate some, but not all behavioral impair-
ments due to neonatal ventral hippocampal lesioning.
However, in the above-mentioned experiment, there was
a clear discrepancy between injury progression and be-
havioral outcome. In contrast to our finding, in adult ro-
dent models of cerebral injury treated with HDACis, func-
tional improvement correlated steadily with neurogenesis
and reduced severity of neurological injury [13–15, 17].
Consistent with these findings, many studies have shown
that experimental reduction of adult neurogenesis impairs
hippocampal memory formation and conversely, stimulat-
ed neurogenesis seems to be one approach to enhance
cognitive recovery. On the other hand, contradictory ac-
counts showed no impact of adult brain neurogenesis re-
duction on memory formation, where the role of newly
generated neurons has previously been strongly suggested
[43, 82, 83]. In the view of this inconsistent data, a stron-
ger link between increased neurogenesis in the injured
brain and functional outcome after treatment with
HDACis needs to be pursued with future work.
In conclusion, the observed protective/neurogenic effect,
following sodium butyrate (SB) treatment in neonatal rats
subjected to hypoxia-ischemia, is associated with a reduc-
tion of brain infarct. It may be due to restoration of
hypoxia-induced loss of neuroblasts and oligodendrocyte
progenitors as well as suppression of microglial cells. In
contrast, the number of new mature granule cells did not
reach the control level, which indicates a limited effect of
SB on this stage of neurogenesis. SB did not appear to
improve neurological outcome; it may be deduced that in
our experimental condition the insufficient number of
cells within the granular cell layer observed after SB treat-
ment does not lead to full compensation for the lost neu-
ronal circuits. Knowledge about the molecular mecha-
nisms of SB action is still in early stage of discovery.
Continuing research along this line may provide a better
understanding of responses to the inhibition of histone
deacetylases in the neonatal hypoxic-ischemic brain.
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